Simultaneous analysis of antiviral effective Favipiravir by green chromatography

Among the scientific researches carried out today, the green chromatography technique, which has been developed to carry out analyzes that prioritize environmental and human health safety, has an important place. Green chromatographic analysis processes can be based on reducing the consumption of harmful solvents or replacing them with more environmentally friendly solvents. In this study, a high-performance liquid chromatography (HPLC) method was developed for the green chromatographic analysis of the antiviral effective favipiravir, which is also used in the treatment of COVID-19, which is used as an internal standard, from the pharmaceutical preparation and validated in accordance with the ICH guideline. In the developed method; Paracetamol (PAR) was used as internal standard and Zorbax C8 (150 × 4.6 mm i.d., 5 µm) analytical column was used for all analyzes. Sodium dihydrogen phosphate buffer (pH 4.2) and ethanol at a concentration of 30 mM, which was used as the mobile phase for chromatographic separation, were mixed at a rate of 97:3 h/h, and the flow rate was determined as 1 mL.min-1. Signals were recorded at a wavelength of 290 nm using a UV detector. The retention times of favipiravir and paracetamol at the selected optimized chromatographic conditions are 5.1 and 8.2 minutes, respectively. The developed methods have been validated according to the stability, originality, linearity, sensitivity, accuracy, precision, consistency and robustness parameters specified in the ICH Q2R1 analytical method validation guide, and their accuracy and reliability have been proven. A linearity range of 1-100 µg.mL-1 was determined for favipiravir, and the limits of detection (LOD); 0.57 µg.mL-1, and the lower limit of detection (LOQ) was found to be 0.90 µg.mL-1. The method developed and validated in this thesis was applied to the analysis of tablet preparations containing favipiravir. Keywords: Favipiravir, green chromatography, HPLC, pharmaceutical analysis, …………….tablet.